Bruker (NASDAQ:BRKR) VP Mark Munch Sells 2,000 Shares

Bruker Corporation (NASDAQ:BRKR) VP Mark Munch sold 2,000 shares of the business’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $52.87, for a total value of $105,740.00. Following the transaction, the vice president directly owned 134,806 shares of the company’s stock, valued at $7,127,193.22. The trade was a 1.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Bruker Price Performance

BRKR stock opened at $60.67 on Thursday. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.85 and a quick ratio of 0.92. The firm has a market capitalization of $9.24 billion, a P/E ratio of -86.67, a P/E/G ratio of 1.71 and a beta of 1.26. The business’s 50-day moving average is $58.09 and its two-hundred day moving average is $49.66. Bruker Corporation has a 1 year low of $30.09 and a 1 year high of $65.30.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.11. The business had revenue of $838.50 million during the quarter, compared to the consensus estimate of $853.57 million. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.The business’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.32 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Analysts anticipate that Bruker Corporation will post 2.12 earnings per share for the current fiscal year.

Bruker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Monday, September 21st will be given a $0.05 dividend. The ex-dividend date of this dividend is Monday, September 21st. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. Bruker’s dividend payout ratio is currently -28.57%.

Institutional Trading of Bruker

Several institutional investors and hedge funds have recently bought and sold shares of the business. Pallas Capital Advisors LLC acquired a new position in Bruker in the second quarter valued at $570,746,000. Sculptor Capital LP grew its holdings in shares of Bruker by 9.0% during the first quarter. Sculptor Capital LP now owns 3,270,000 shares of the medical research company’s stock worth $118,112,000 after buying an additional 270,000 shares during the last quarter. Edmond DE Rothschild Holding S.A. acquired a new position in Bruker in the 2nd quarter valued at about $169,899,000. Dimensional Fund Advisors LP raised its stake in Bruker by 23.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,341,518 shares of the medical research company’s stock valued at $84,556,000 after acquiring an additional 448,440 shares during the last quarter. Finally, Franklin Resources Inc. lifted its position in Bruker by 317.7% during the 4th quarter. Franklin Resources Inc. now owns 2,309,404 shares of the medical research company’s stock worth $108,796,000 after acquiring an additional 1,756,460 shares during the period. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on BRKR shares. TD Cowen reissued a “hold” rating on shares of Bruker in a report on Wednesday, July 15th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Bruker in a research report on Monday, August 31st. UBS Group assumed coverage on shares of Bruker in a research note on Wednesday, September 9th. They set a “neutral” rating and a $65.00 price target on the stock. Guggenheim upped their price objective on shares of Bruker from $50.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Finally, Zacks Research cut Bruker from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 2nd. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Bruker presently has an average rating of “Hold” and a consensus price target of $57.00.

About Bruker

Bruker Corporation develops and manufactures scientific instruments, analytical systems and software used to study the chemical, physical and biological properties of materials. Its customers include universities, pharmaceutical and biotechnology companies, industrial manufacturers, hospitals, government laboratories and other research organizations.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray analysis instruments, optical and molecular spectroscopy systems, microscopy and nanoanalysis tools, and instruments for microbiology and spatial biology.